Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 78 Week Open Label Extension to Trials Assessing the Safety and Efficacy of BI 10773 as Monotherapy or in Combination With Metformin in Type 2 Diabetic Patients
Brief Summary: The objective of the current study is to investigate the safety and efficacy of BI 10773 in 2 different doses compared to Metformin or to Sitagliptin given for 78 weeks in different modalities of treatment in patients with type 2 diabetes mellitus.


Options:
A: Arm Label: 1.5 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Insulin Lispro | Arm Label: 0.75 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Insulin Lispro | Arm Label: Insulin Glargine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin Glargine, Drug: Insulin Lispro | Intervention Type: DRUG; Name: Insulin Glargine; Assigned to Arm(s): Insulin Glargine | Intervention Type: DRUG; Name: LY2189265; Assigned to Arm(s): 0.75 mg LY2189265, 1.5 mg LY2189265 | Intervention Type: DRUG; Name: Insulin Lispro; Assigned to Arm(s): 0.75 mg LY2189265, 1.5 mg LY2189265, Insulin Glargine
B: Arm Label: Saxagliptin and Metformin (A); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Metformin, Drug: pioglitazone | Arm Label: Saxagliptin and Metformin (B); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Metformin, Drug: pioglitazone | Arm Label: Saxagliptin and Placebo (C); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Placebo, Drug: pioglitazone | Arm Label: Metformin and Placebo (D); Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Placebo, Drug: pioglitazone | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin and Metformin (A), Saxagliptin and Placebo (C) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin and Metformin (B) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin and Placebo (D), Saxagliptin and Metformin (A), Saxagliptin and Metformin (B) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Metformin and Placebo (D), Saxagliptin and Placebo (C) | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Metformin and Placebo (D), Saxagliptin and Metformin (A), Saxagliptin and Metformin (B), Saxagliptin and Placebo (C)
C: Arm Label: Sitagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: BI 10773 X mg; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 | Arm Label: BI 10773 Y mg; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 Y mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 X mg | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin
D: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Empagliflozin; Type: ACTIVE_COMPARATOR; Interventions: Drug: empagliflozin | Intervention Type: DRUG; Name: empagliflozin; Assigned to Arm(s): Empagliflozin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin

Answer: C